Palisade Bio is a Denver-based, clinical-stage biopharmaceutical company developing oral phosphodiesterase-4 (PDE4) inhibitor prodrugs for inflammatory bowel disease. It is a stock, not an ETF, so its price target is derived from analyst research rather than fund holdings or flows.
Reviewing recent, individually attributed targets yields nine usable figures: Piper Sandler at $16 (November 11, 2026), Clear Street at $12, Oppenheimer at $8, Maxim Group at $8, B. Riley Securities at $7, Wolfe Research at $7, Raymond James at $6, H.C. Wainwright at $5, and Stifel at $5. The simple average is about $8.20, which rounds to a central target of $8. This is not an official published consensus; reputable aggregators currently report slightly different averages because of timing and methodology differences.
The $5-to-$16 range is unusually wide, underscoring how much analyst opinions diverge. Most firms rate the stock Buy or Outperform, but recent actions have been cautious in direction. In November 2026, Piper Sandler cut its target from $25 to $16 and H.C. Wainwright cut from $7 to $5, even as both kept positive ratings. The general analyst rationale is that PALI-2108's early data supports meaningful upside, but the stock's price reflects deep skepticism about a pre-revenue biotech with distant data readouts. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.
Palisade Bio shares closed near $1.12 in mid-November 2026, near the low end of a 52-week range of roughly $1.08 to $2.86. A move to $8 would represent an increase of about 614% — a very large move by any standard, and one that would require the stock to exceed its recent 52-week high more than two-and-a-half times over.
The path to such a level runs almost entirely through clinical execution. The company's lead candidate, PALI-2108, has reported Phase 1b data in fibrostenotic Crohn's disease showing 40% endoscopic remission and 40% endoscopic response. The next major milestone is the open-label Phase 2a ASCENTRA-CD trial, expected to begin in the first quarter of 2027, with a potential interim readout in the second half of 2027 and a primary efficacy readout in early 2028.
Positive, de-risking clinical data is the central bull case. Analysts including Piper Sandler have argued the market under-appreciates PALI-2108's catalyst path, and that Phase 1b results help de-risk the larger Phase 2a trial. The company also reported roughly $133 million in cash as of early 2026, which may fund operations through near-term catalysts. Broader sentiment toward innovative inflammatory bowel disease therapies and any partnership or licensing activity could add further support.
The risks are substantial. Palisade Bio is pre-revenue and consistently unprofitable, posting a quarterly loss of $0.07 per share in its most recent report, slightly worse than the $0.06 consensus estimate. Its value depends almost entirely on PALI-2108, and any clinical setback, delay, or dilution from future equity raises could pressure the stock. The shares have declined sharply over the past year and sit near their 52-week low, indicating that the market currently assigns little credit to the bullish analyst targets.
The stock's price action is weak. Shares trade below their 50-day and 200-day moving averages and near the 52-week low around $1.08, which is the most relevant nearby support level. On the upside, the prior 52-week high near $2.86 and round psychological levels in the low single digits represent meaningful resistance. The wide gap between the current price and even the lowest analyst target reflects a market that is pricing the stock primarily on execution risk rather than on projected value.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may apply different assumptions. The most important items to watch are the initiation and enrollment of the ASCENTRA-CD Phase 2a trial, any interim efficacy data, further analyst target revisions, quarterly cash-burn updates, and any financing or partnership announcements. Earnings guidance matters less for a pre-revenue biotech, but cash runway and trial timelines are critical.
In my view, tools like Tickeron’s AI Trend Prediction Engine can help investors track technical patterns and sentiment shifts in volatile names like this one, providing an additional layer of insight alongside traditional research. From what I see, combining these signals with clinical timelines gives a clearer picture of potential inflection points without replacing fundamental due diligence.
Can Palisade Bio reach $8? The $8 central target is the rounded average of nine analyst targets spanning $5 to $16, and it implies a move of roughly 614% from the current price near $1.12 — an extraordinarily large gap that reflects both the promise of PALI-2108 and the market's profound skepticism. Support rests on early clinical data and upcoming trial catalysts, while the principal obstacles are the company's pre-revenue status, ongoing losses, and a stock trading near its 52-week low. The targets are not a guarantee, and the wide analyst range shows that even bullish firms disagree sharply on magnitude. Investors should monitor clinical milestones and cash runway above all.
I’ve found Tickeron’s AI Daily Buy/Sell Signals particularly useful for monitoring stocks like Palisade Bio. The platform applies artificial intelligence to scan thousands of securities in real time, generating signals based on technical and market changes. This can streamline the process of spotting shifts in trend or volatility, especially for a clinical-stage name driven by upcoming data readouts. It serves as one more resource alongside analyst reports and trial updates.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
PALI saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 90 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PALI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Indicator exited the oversold zone, 34 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for PALI just turned positive on November 04, 2026. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in 168 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PALI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.618) is normal, around the industry mean (3.498). P/E Ratio (1.738) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds
Industry Biotechnology